Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

Arbor. "As a specialty pharmaceutical company already focused in the cardiovascular area, we are well-positioned to ensure the EDARBI products are available to all appropriate patients who may need them."

About Hypertension
Hypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated to levels of 140 mm Hg or greater systolic and/or 90 mm Hg or greater diastolic. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of blood pressure in individuals with severe hypertension can provide substantial benefit.

Hypertension impacts approximately 67 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation's health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About EDARBI and EDARBYCLOR
EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) developed by Takeda for the treatment of hypertension to lower blood pressure in adults. EDARBI lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone, which naturally exists within the body. When EDARBI blocks the angiotensin II receptor, blood vessels can stay relaxed and open, and blood pressure can be reduced. EDARBI is indicated for the treatment of hypertension to lower blood pressure in adults, either alone or in combination with other antihypertensive
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
(Date:5/22/2015)... 22 2015 /CNW/ - The Taskforce representing Canada,s ... all the hard work that the Minister and Health Canada ... This program recognizes the needs of the thalidomide survivors, and ... a year, tax free, with annual adjustments for inflation. ... annual payments of $100,000 based on the severity of their ...
(Date:5/22/2015)... , May 22, 2015  Amgen ... Company has commenced termination of its participation ... with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... is in development for patients with moderate-to-severe ... The decision was based on events of ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... and distributor of patented products, launches The Preventer, a ... property from the dangers of fire. , "House fires ... yearly," says Scott J. Cooper, CEO and Creative Director ... of home fire deaths result from homes that have ...
(Date:5/25/2015)... World Patent Marketing, a vertically integrated ... Little Party Table, a party invention that gives people ... suit their party needs. , "Worldwide indoor and outdoor ... past year. Party Supply Rentals alone are a ... CEO and Creative Director of World Patent Marketing ...
(Date:5/25/2015)... 2015 World Patent Marketing, a vertically ... Hidee-Hose, an undergarment patent that allays women’s fears when ... Hosiery industry forecasts the market to reach $20.3 billion ... Director of World Patent Marketing , "The largest ... and is expected to maintain its lead. The industry ...
(Date:5/25/2015)... HomeCare is proud to announce that David Allerby, Co-Founder ... Iwamoto, Co-Founder & CMO, are Finalists for the Ernst ... Greater Los Angeles. The award is presented by EY ... and a personal commitment to their communities. , “Our ... of our organization,” said Co-Founder & CEO, David Allerby, ...
(Date:5/25/2015)... 2015 According to a recently published ... in hip external fixation market is driven by an ... and advancements in infection prevention technologies. As the population ... currently accounting for the largest total number of bone ... and accidents. As a result, the average selling price ...
Breaking Medicine News(10 mins):Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3
... meets tight deadlines and reduces costs , ... Portland, ... announced the launch of its PeerPoint® Medical Review Portal software. ... to send and receive independent medical reviews via the web. ...
... AIDS Vaccine, Microbicide and PrEP Research and Calls for Urgent ... May 18 "It,s an exciting time in HIV prevention ... important HIV prevention research trials this year, as well as ... will yield important answers in the years to come," said ...
... into muscles , , SUNDAY, May 17 -- Raising hopes ... actually work, researchers report they were able to protect ... primate version of HIV. , They did so by ... to the animals, muscles. Typically, vaccines are aimed at ...
... DIEGOA large, well-controlled, multi-national clinical trial program has ... become the first FDA-approved medicine for idiopathic pulmonary ... study program called "CAPACITY," investigators discovered that the ... the deterioration of lung capacity in patients suffering ...
... (May 17, 2009)The COPD Foundation announces launch of the ... WebMD. Development of the Lung Health Check was made ... , The Lung Health Check is an educational platform ... symptoms and risks of developing lung disease, and suggests ...
... to avoid being attacked , , SUNDAY, May 17 (HealthDay News) ... can be unpredictable, warns the American College of Emergency Physicians ... each year, according to the U.S. Centers for Disease Control ... In 2006, more than 31,000 people had to have reconstructive ...
Cached Medicine News:Health News:AllMed's New PeerPoint Medical Review Portal Improves Medical Review Process 2Health News:AllMed's New PeerPoint Medical Review Portal Improves Medical Review Process 3Health News:Piecing Together the HIV Prevention Puzzle 2Health News:Piecing Together the HIV Prevention Puzzle 3Health News:Piecing Together the HIV Prevention Puzzle 4Health News:Vaccine Shields Monkeys From Simian Form of HIV 2Health News:Vaccine Shields Monkeys From Simian Form of HIV 3Health News:Large clinical trial finds pirfenidone may help lung function in IPF patients 2Health News:Large clinical trial finds pirfenidone may help lung function in IPF patients 3Health News:COPD Foundation announces launch of Lung Health Check on WebMD 2Health News:Beware of Dog Bites 2
Bravo Calibration Tubes...
The pouch is designed to protect the Digitrapper. The pouch strap can be worn on a belt loop or carried in a shoulder strap or backpack configuration....
pHix Strips easily fix the catheter on the nose and are made of microporous tape allowing the skin to breathe....
... proper gel is essential in ... working with pH catheters with ... chloride ion concentration in the ... for proper function of your ...
Medicine Products: